trial summary · NCT07135882
Primary Radiotherapy In MEtastatic Lung Cancer
A Randomised Phase III Trial of Up-front Radiotherapy With Standard-of-care Systemic Therapy in Advanced Lung Cancer
Trial record from the TrialBase DB dataset, status RECRUITING, condition Carcinoma, Non-Small-Cell Lung (NSCLC), sponsored by Trans Tasman Radiation Oncology Group. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
Lung cancer has the highest mortality rate of all cancers in Australia and is an area of unmet need. It starts in the lung (the primary tumour), and then spreads (metastasise) to other organs. The PRIME-Lung clinical trial will investigate if radiotherapy to the primary lung tumour, in addition to standard drug therapies, for patients with metastatic lung cancer will lead to less spread of cancer, prolong life, improve patient well-being and be cost-effective for the health care system.
Source record: https://clinicaltrials.gov/study/NCT07135882
Facts
| registry id | NCT07135882 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE3 |
| study type | INTERVENTIONAL |
| lead condition | Carcinoma, Non-Small-Cell Lung (NSCLC) |
| sponsor | Trans Tasman Radiation Oncology Group |
| sponsor class | OTHER |
| enrollment | 420 |
| start date | 2026-10-30 |
| primary completion | 2030-12-31 |
| completion | 2036-12-31 |
| results posted | not reported |
Conditions
- Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions
- Radiotherapy followed by chemotherapy
- Standard of Care (SOC)
Countries
- Australia
Intervention types: COMBINATION_PRODUCT, DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.